Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
12/05/2025 22:02
Akoya Biosciences Inc AKYA.OQ reported a quarterly adjusted loss of 32 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -48 cents. The mean expectation of eight analysts for the quarter was for a loss of 20 cents per share. Wall Street expected results to range from -23 cents to -17 cents per share. Revenue fell 9.3% to $16.64 million from a year ago; analysts expected $19.95 million. Akoya Biosciences Inc's reported EPS for the quarter was a loss of 32 cents. The company reported a quarterly loss of $15.65 million. Akoya Biosciences Inc shares had fallen by 20.9% this quarter and lost 52.0% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 3.1% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "hold" Wall Street's median 12-month price target for Akoya Biosciences Inc is $3.00 This summary was machine generated from LSEG data May 12 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.20 | -0.32 | Missed |
| Dec. 31 2024 | -0.16 | -0.17 | Missed |
| Sep. 30 2024 | -0.20 | -0.21 | Missed |
| Jun. 30 2024 | -0.27 | -0.27 | Met |
Recent news on Akoya Biosciences
See all newsBrief: Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks